In addition, treatment with nicardipine, an ABCG2 competitive inhibitor, sensitized CD133-positive glioma stem cells to mitoxantrone, whereas no synergistic effect was observed in CD133-negative tumor cells. The gene discussed is PROM1; the disease is central nervous system cancer.